Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study

Author:Bermel, Robert   Hartung, Hans-Peter   Brochet, Bruno   Benedict, Ralph   Berger, Thomas   Carroll, William   Vollmer, Timothy   Holmoy, Trygve   Karabudak, Rana   Killestein, Joep   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Wuerfel, Jens   Kuenzel, Thomas   Kadner, Karen   Kulyk, Inessa   Freedman, Mark   

Session Name:S46: MS Therapeutics and Clinical Decision Making  

Topic:MS and Inflammatory Disease  

Program Number:S46.004  

Author Institution:Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Deptartment of Neurology, Heinrich-Heine-University Düsseldorf, Germany, Dusseldorf, Germany  Université de Bordeaux, Neurocentre Magendie INSERM, Bordeaux, France, Bordeaux, France  Jacobs School of Medicine and Biomedical Sciences, Department of Neurology, University of Buffalo, NY, USA, Buffalo, NY  Dept. of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA, Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute Ottawa, ON, Canada., Ottawa, ON, Canada  

Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

Author:Williams, Mitzi   Airas, Laura   Chitnis, Tanuja   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Dörner, Thomas   Loop, Brett   Ziehn, Marina   Willi, Roman   Kieseier, Bernd C.   Nikolaev, Ivan   Haemmerle, Sibylle   Zharkov, Artem   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Giménez-Arnau, Ana   Montalban, Xavier   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.015  

Author Institution:Joi Life Wellness Group, Atlanta, GA, USA, Atlanta, GA  Turku University Hospital and University, Finland, Turku, Finland  Brigham and Women's Hospital, Department of Neurology, Boston, MA, USA, Boston, MA  Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA, Baltimore, MD  Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, Hiroshima, Japan  University of Toronto, Toronto, Ontario, Canada, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin  DRFZ, Berlin, Germany, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA, USA, Cambridge, MA  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland  Department of Neurology, Heinrich-Heine University, Duesseldorf, Germany, Duesseldorf, Germany  Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany  Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany, Berlin, Germany  Department of Dermatology, Hospital del Mar - IMIM, Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain